Drug Trial Radar · NCT05171647
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
208
Actual
Start
Apr 25, 2022
Primary completion
Feb 17, 2025
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).
Conditions
- Non-Hodgkin Lymphoma
Interventions
MosunetuzumabDrug
Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).
Polatuzumab vedotinDrug
Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).
TocilizumabDrug
Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.
RituximabDrug
Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
GemcitabineDrug
Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
OxaliplatinDrug
Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)Time frame: Up to approximately 23.8 months
- Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT ScansTime frame: Up to 32 months
Locations
50 sites in 13 countries. Site status is shown where the registry gives one.
City of Hope Cancer Center
Duarte, California
St. Luke's Hospital
Chesterfield, Missouri
Ascension Seton Infusion Center
Austin, Texas
MD Anderson Cancer Center
Houston, Texas
Hospital Aleman
Buenos Aires, Argentina
Instituto Alexander Fleming
Buenos Aires, Argentina
FUNDALEU
Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
Ciudad Autonoma Buenos Aires, Argentina
D'or Instituto de Pesquisa e Educação
São Paulo, Brazil
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clínicas FMRP-USP
Ribeirão Preto, São Paulo, Brazil
Hospital Sao Jose
São Paulo, São Paulo, Brazil
Princess Margaret Hospital
Toronto, Ontario, Canada
Chum Hopital Notre Dame
Montreal, Quebec, Canada
Sichuan Cancer Hospital
Chengdu, China
Fujian Medical University Union Hospital
Fuzhou, China
Cancer Center, Sun Yat-sen University of Medical Sciences
Guangzhou, China
Tianjin Cancer Hospital
Tianjin, China
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
Wuhan, China
Henan Cancer Hospital
Zhengzhou, China
Soroka Medical Center
Beersheba, Israel
Ichilov Sourasky Medical Center
Tel Aviv, Israel
Kyushu University Hospital
Fukuoka, Japan
Hokkaido University Hospital
Hokkaido, Japan
Tohoku University Hospital
Miyagi, Japan
Kindai University Hospital
Osaka, Japan
The Cancer Institute Hospital of JFCR
Tokyo, Japan
Yamagata University Hospital
Yamagata, Japan
Instituto Nacional de Cancerologia
Distrito Federal, Mexico
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
México, Mexico
Superare Centro de Infusion S.A. de C.V.
Mexico City, Mexico CITY (federal District), Mexico
Hospital Universitario Dr. Jose E. Gonzalez
Monterrey, Nuevo León, Mexico
Middlemore Clinical Trials
Auckland, New Zealand
Instituto Regional de Enfermedades Neoplásicas del Sur
Arequipa, Peru
Oncosalud Sac
Lima, Peru
Pusan National University Hospital
Busan, South Korea
Chungnam National University Hospital
Daejeon, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.